Horizon touts PhIV win for Tepezza; FDA sets adcomm dates for Sarepta, Pfizer, Eisai apps
Horizon Therapeutics’ Tepezza, which treats a rare autoimmune disease that affects the eye, has cleared a Phase IV trial designed to illustrate the drug’s use in a specific patient population with chronic thyroid eye disease.
The biotech — which is set to become part of Amgen once its $28.3 billion deal goes through — targeted thyroid eye disease patients with low clinical activity scores for the trial. The primary endpoint was measured by proptosis or the bulging of one or both eyes from the natural position.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.